No Data
No Data
AstraZeneca (AZN) Receives a Buy From Goldman Sachs
TRUQAP (Capivasertib) Combination in PTEN-deficient Metastatic Hormone-sensitive Prostate Cancer Demonstrated Statistically Significant and Clinically Meaningful Improvement in Radiographic Progression-free Survival in CAPItello-281 Phase III Trial
AstraZeneca's Truqap Combo Demonstrated Statistically Significant Improvement
GCAR and AstraZeneca Execute Agreement to Evaluate AZD1390 for Glioblastoma
AstraZeneca's Prostate Cancer Treatment Trial Shows Clinically Meaningful Improvement
AstraZeneca (AZN): A Top Pick for Hedge Funds Due to Innovation and Rising Demand
loading...
No Data
No Data